FDA Issues CRL for Parkinson’s Therapy
The FDA is asking for additional analysis related to the infusion device used with SPN-830, which contains apomorphine to treat patients with Parkinson’s disease.
The FDA has issued a complete response letter (CRL) for the Supernus Pharmaceuticals’ new drug application for SPN-830. SPN-830 is an apomorphine infusion device under review to treat short-term, intermittent “off” episodes in people with Parkinson’s disease. The infusion device would create a continuous treatment with apomorphine.
The FDA is asking for additional analysis related to the infusion device used with SPN-830. The agency is also requiring inspections of manufacturing facilities.
Jack Khattar
“SPN-830 remains a key priority for Supernus as there is a need to provide a minimally invasive therapy for PD patients who are experiencing motor fluctuations not adequately controlled with current treatment options,” Jack Khattar, president and CEO of Supernus, said in a press release. “We are committed to Parkinson’s disease patients and to working with the FDA to address the CRL issues so that we can put the NDA back on track toward potential U.S. approval.”
The company had resubmitted the NDA in December 2021 following the agency’s initial refusal to file the application because it was incomplete.
Related: FDA Updates Warning Labels on Parkinson’s Therapies
Supernus markets Apokyn, an injection form of apomorphine but in February 2022, a first generic was approved. The generic was only for Sage Chemical’s drug cartridge, which is compatible for use with the Apokyn pen. It has already been removed from several formularies, including Cigna and Prime Therapeutics, and sales of the therapy have started to slip. In the first half of this year, sales of Apokyn are down 20%.
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More
